Arcellx, Inc. Financial Analysis
Current Price: $115.07 +0.02%
Market Cap: $6.73B
Sector: Healthcare
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-
Report Contents
- Income Statement Analysis (5-year history)
- Balance Sheet Overview
- Cash Flow Statement
- Key Financial Ratios
- Valuation Metrics (P/E, EV/EBITDA, P/S)
- Peer Comparison
- Revenue & Earnings Growth Trends
- Margin Analysis
- Analyst Price Targets
- DCF Valuation Model